對於費城染色體陽性的ALL病患治療結果：

罹患急性淋巴性白血病(ALL)的患者，出現費城染色體(Philadelphia chromosome, Ph chromosome)及（或）BCR-ABL基因陽性的比率有隨著年齡增加而增加的趨勢（兒童時期為＜5%， ... °òª÷·|»PÂø»x|§ÜÀù¸ê°T |·|­ûµù¥U|¯f¤Í¶é¦a|ÂåÀøÅU°Ý |³Ì·s¤åÄm|¬ÛÃöºô¯¸|½u¤W®½´Ú |³Ì·s®ø®§ ¹ï©ó¶O«°¬V¦âÅ鶧©ÊªºALL¯f±wªvÀøµ²ªG¡G LALA-94«e¤©ÊÁ{§É¸ÕÅç OutcomeoftreatmentinadultswithPh+ALL-resultsoftheprospective multicenterLALA-94trial Blood,Vol.100,2002:2357-66 ByHerve¡¦Dombret,JeanGabert,Jean-MichelBoiron,etal. ĶªÌ¡G¾H¥ò¤¯ ¤@¡B¬ã¨s­I´º»P¥Øªº ¿©±w«æ©Ê²O¤Ú©Ê¥Õ¦å¯f(ALL)ªº±wªÌ¡A¥X²{¶O«°¬V¦âÅé(Philadelphiachromosome,Phchromosome)¤Î¡]©Î¡^BCR-ABL°ò¦]¶§©Êªº¤ñ²v¦³ÀHµÛ¦~ÄÖ¼W¥[¦Ó¼W¥[ªºÁͶա]¨àµ£®É´Á¬°¡Õ5%¡A¦¨¤H®É´Á«h¼W¥[¦Ü40%¥H¤W¡^¡A¦Ó¦¹¤GªÌ§¡¬O¯e¯f¤£¨Îªº¹w«á¦]¤l¡C¦]¦¹¥»¶µ«e¤©ÊÁ{§É¸ÕÅç°lÂܤF154¦W¿©±w«æ©Ê²O¤Ú©Ê¥Õ¦å¯f(ALL)ªº¯f±w¶O«°¬V¦âÅ鶧©Ê©Î/¨ÖBCR-ABL°ò¦]¶§©Ê¡A¥Øªº¦bµû¦ô¯fµ{¦­´Á¹ïªvÀø¦³¤ÏÀ³ªº¹w«á»ù­È¡A¥H¤Î·F²Ó­M²¾´Ó¦b²Ä¤@¶¥¬q§¹¥þ½w¸Ñ(first completeremission,firstCR)©Ò§êºtªº­«­n©Ê¡C ¤G¡B¬ã¨s¹ï¶H»P¤èªk ¦è¤¸1994¦Ü2000¦~¡A¦³154¦W¿©±w«æ©Ê²O¤Ú©Ê¥Õ¦å¯f(ALL)ªº¯f±w¶O«°¬V¦âÅ鶧©Ê©Î/¨ÖBCR-ABL°ò¦]¶§©Ê±µ¨ü¥»¶µ«e¤©ÊªºÁ{§É¸ÕÅç¡]¥­§¡°lÂܮɶ¡¬°4.5¦~¡^¡C¥L­Ì§¡±µ¨ü¼Ð·Ç¤Æªº»¤¾ÉÀøµ{(induction course)¡AÄ~¤§¥Hmitoxantrone¤Î¤¤µ¥¾¯¶qªºcytarabine(HAM)¡C¦b¨C¤@¬qÀøµ{¤§«á¡A¨ä·L¶q´Ý¾l¸~½F(minimal residualdisease,MRD)«h¥H¤ÏÂà¿ý¦h¤ë¤Ó×QÃì¤ÏÀ³(rt-PCR)°»´ú¤§¡]¥­§¡±Ó·P«×¬°10-5¡^¡C¯f±w¦bHAMÀøµ{¤§«á¤T­Ó¤ë¡A­Y¶i¤J§¹¥þ½w¸Ñ´Á(CR)¡A«h±µ¨ü²§Åé¡]­Y¦³¦X¾A®½Ãت̡^©Î¦ÛÅé¡]­YµL¦X¾A®½Ãت̡^·F²Ó­M²¾´Ó¡C ¤T¡B¬ã¨sµ²ªG ¦b»¤¾ÉÀøµ{«á¡BHAMÀøµ{«á¤Î¤T­Ó¤ë«áªº§¹¥þ½w¸Ñ(CR)²v¤À§O¬O¡G53%¡B67%¤Î62%¡C¹ï©ó¦b¤T­Ó¤ë®Éªº§¹¥þ½w¸Ñ(CR)¡A¥Õ¦å²y¼Æ¥Ø¸û°ª¤Îm-bcr¨È«¬¬O¤w³QÃҹꪺ¤£¨Î¹w«á¦]¤l¡F¦¹¤GªÌªº¯f±w¦b»¤¾ÉÀøµ{ªº²Ä8¤Ñ§Y¥X²{¤£¨ÎªºÃĪ«¤ÏÀ³²v¡CHAMÀøµ{©Ò³y¦¨ªº±þ¸~½F¤ñ²v(HAM-associated salvagerate)¡A¦b«æ©Ê²O¤Ú©Ê¥Õ¦å¯f(ALL)M-bcr¨È«¬¸ûm-bcr¨È«¬¬°°ª¡]55%vs30%¡AP­È¡Õ0.05¡^¡C¾A¦X°µ·F²Ó­M²¾´ÓªÌ¦³103¦W¡A¹ï¥L­Ì¦Ó¨¥¡A²§Åé·F²Ó­M²¾´Ó»P§_¤ÎHAMÀøµ{«áBCR-ABL°ò¦]¬O§_§e³±©Ê¡A¬Ò¯à¿W¥ß¦a¹w´ú«ùÄò½w¸Ñ´Á¡]P­È¤À§O¡Õ0.001¡B¡Õ0.01¡^¡A¥H¤Î¦s¬¡²v¡]P­È¤À§O¡Õ0.02¡B¡Õ0.01¡^¡C ¥|¡Bµ²½× ³Ì±`³y¦¨¯f±wªvÀø¥¢±Ñªº­ì¦]¬O¯e¯fªº´_µo¡C¹ï©ó¿©±w¦¹¯fªº¦¨¤H¡A¦b²Ä¤@¶¥¬q§¹¥þ½w¸Ñ³Ì¾A¦XªºªvÀøµ¦²¤À³¬O²§Åé·F²Ó­M²¾´Ó¡C¦¹¥~¡A¹ï©ó¯e¯f¦­´ÁªvÀøªº·sÀøµ{¤´¦³«Ý¬ã¨s¡A¥H¼W¥[BCR-ABL°ò¦]³±©Ê½w¸Ñ²v¡C     µn¿ý®É¶¡¡G91¦~12¤ë6¤é